NEW LOCATION! Our Store has moved to 64 Mountainview Blvd, Wayne, NJ

    Access Bio RCPM-00271 Carestart COVID-19 Antigen Home Rapid Self-Test - 2/bx *DISCONTINUED*

    By Access Bio | Mfr#: RCPM-00271 | Tiger#: TS93867


    • Rapid Detection of Sars-CoV-2 Virus
    • For Point-of-Care Testing or Home Use
    • Can be used for Symptomatic and Asymptomatic Children & Adults
    • Non-Invasive & Comfortable Testing w/ Fast & Accurate Results in Just 10 Minutes
    • Authorized by FDA under Emergency Use Authorization
    • Has Mobile App w/ Step-by-Step Test Instructions
    • Sensitivity: 87.2%
    • Specificity: 100%


    More Product Details What's Included
    List Price: $54.00
    You Save: $24.05 - 45%
    Availability:Out Of Stock
    Ships Out Within: Discontinued
    Tiger Supplies no longer carries this item
    • Under Emergency Use Authorization (EUA) Only

    • For In Vitro Diagnostic Use

    • EXPIRATION DATE: March 2022 [Has been extended as approved by FDA]

    Overview for Access Bio RCPM-00271 Carestart COVID-19 Antigen Home Rapid Self-Test - 2/bx

    The Access Bio Carestart COVID-19 Antigen Home Rapid Self-Test is a non-invasive and easy to use antigen test, used for home use or point-of-care testing, to determine active covid-19 infection in a patient through nasal (nares) swabbing. Fast and precise results can be obtained within 10 minutes, which can greatly help individuals and healthcare professionals be aware of the situation, and provide proper diagnosis and action.

    Simple & Efficient: This COVID-19 Antigen Rapid Test was made by Access Bio to quickly detect Sars-CoV-2 nucleocapsid protein antigen in a person. Any symptomatic patient, ages 2 and above, within the first 7 days of their symptoms, can be tested. This Antigen Self-Test can also be used in an individual without symptoms or have other epidemiological reasons to suspect Covid-19, when tested twice over three days (with a 24 hours interval). 

    Quick & Easy to Use: The sample can be obtained, either self-collected or adult-collected, by brushing the nasal swab 5 times against the inner wall of both nostrils of a patient. You can effectively get a sample just by inserting 1/2 to 3/4-inch of the swab inside the nose, since this test kit promotes optimal comfort for the user. The specimen is then mixed with the solution inside the extraction vial, thoroughly mixing 5 times to make sure that all the samples collected are incorporated with the buffer solution. Simply put 3 drops of the solution in the sample well of the kit’s test cassette, and wait for 10 minutes. Its sensitivity is 87.2 percent while specificity is 100 percent.

    Accurate & Fast Result: Please take note that accurate results will be shown 10 minutes after applying the sample and should not exceed 15 minutes to avoid reading false positive or negative results. A solo purple horizontal mark on the "C" (control) area depicts that you have a negative result, while a positive result shows two colored marks for the "C"  and "T" (test) zones. Invalid results show no lines on the "C" zone. 

    Digitally-Compatible Rapid Test: You can administer this Home Rapid Test with the help of its mobile application, which can be downloaded through your mobile’s App Store or on the provided QR code in the package box and the User Manual. The On/Go Mobile Application has an in-app self-paced step-by-step instructions on how to administer the Carestart COVID-19 Antigen Home Rapid Self-Test in the comfort of your home. 

    FDA Disclaimer: This swab test kit is not FDA cleared or approved, but only authorized under an Emergency Use Authorization for home use or point of care use. It is authorized for the rapid detection of proteins from SARS-CoV-2 and not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(2), unless the declaration is terminated or authorization is revoked sooner.